Infliximab for Crohn's disease in clinical practice: The experience of a single center in Romania

Romanian Journal of Gastroenterology

Volumn 12, Issue 1, 2003, Pages 7-13

  Gheorghe, Liana ^a   Gheorghe, Cristian ^a   Badea, Mihaela ^a   Vǎdan, Roxana ^a   Pârvulescu, Iuliana ^a   Toader, Cristina ^a   Tugui, Letiţia ^a   Papuc, Octavian ^a   Ionescu, Radu ^a   Preda, Carmen ^a   Cǎlin, Ion ^a   Diculescu, Mircea ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Crohn's disease; Infliximab; Tumor necrosis factor

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; GASTROINTESTINAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COLITIS; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DYSPNEA; ENDOMETRITIS; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MUCOSA; HUMAN; HYPOTENSION; ILEUM POUCH; ILEUM RESECTION; IMMUNOTHERAPY; MALE; MYALGIA; PREGNANCY; RECTUM FISTULA; REMISSION; ROMANIA; SEPSIS; SOMNOLENCE; STUPOR; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; ULCER HEALING; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037358959     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96: 635-643
2. Gasehe C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15
3. REMICADE package insert. Malvern: Centocor, 1999
4. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
5. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-1035
6. Rutgeerts P, D'Haens G, Targan SR, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769
7. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729
8. Present DH, Rutgeerts P, Targan SR, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405
9. Best WR, Becktel JM, Singleton JW. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
10. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846
11. Moum B, Eckbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway 1990-1993. Scand J Gastroenterol 1997; 32: 1005-1012
12. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362
13. Mekhjian HS, Switz DM, Watts HD, et al. National Cooperative Crohn's Disease Study. Factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979; 77: 907-913
14. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963
15. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987
16. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17 (Suppl): S176-S185
17. Cellier C, Sahmoud T, Froguel E, et al. and the GETAID. Correlation between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonie Crohn's disease. A prospective multicenter study of 121 cases. Gut 1994; 35: 231-235
18. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 1808-1817.
19. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-1481
20. D'Haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease. A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
21. Sandborn WJ. Steroid-dependent Crohn's disease. Can J Gastroenterol 2000; 14 (Suppl C): 17C-22C
22. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-1723
23. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14 (Suppl C): 29C-32C